Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Hagemann

Showing results (111-120 of 132) with videos related to

Pageof 14
Sort By:
Gynecologic Oncology|July 6, 2024
A toolkit for a modern gynecologic oncology tissue bankOlivia Graham, Jeimmy Rodriguez, Rachel Abbott, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophagesXiaoqing Cheng, Khooshbu Kantibhai Patel, Brandon Zhou, et al.
NPJ Breast Cancer|January 7, 2023
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, et al.
Molecular Cancer Research : MCR|October 21, 2021
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication StressMary M Mullen, Elena Lomonosova, Michael D Toboni, et al.
Cancer Immunology Research|February 6, 2026
Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trialRashmi Mishra, Foluso Ademuyiwa, Yilin Yang, et al.
Communications Biology|July 3, 2023
Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survivalEmilee N Kotnik, Mary M Mullen, Nicholas C Spies, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2025
Targeting RAD52 overcomes PARP inhibitor resistance in preclinical <i>Brca2</i>-deficient ovarian cancer modelYukihide Ota, Vijayalaxmi Gupta, Bisiayo E Fashemi, et al.
Cancer Immunology Research|June 17, 2017
Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor ImmunityXiuli Zhang, Samuel Kim, Jasreet Hundal, et al.
The Journal of Clinical Investigation|May 20, 2025
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancerAngela Schab, Amanda Compadre, Rebecca Drexler, et al.
Molecular Cancer Research : MCR|August 1, 2023
Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix ProteinsAngela M Schab, Molly M Greenwade, Elizabeth Stock, et al.
Pageof 14

Showing results (111-120 of 132) with videos related to

Sort By:
Pageof 14
Gynecologic Oncology|July 6, 2024
A toolkit for a modern gynecologic oncology tissue bankOlivia Graham, Jeimmy Rodriguez, Rachel Abbott, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophagesXiaoqing Cheng, Khooshbu Kantibhai Patel, Brandon Zhou, et al.
NPJ Breast Cancer|January 7, 2023
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)Foluso O Ademuyiwa, Donald W Northfelt, Tracey O'Connor, et al.
Molecular Cancer Research : MCR|October 21, 2021
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication StressMary M Mullen, Elena Lomonosova, Michael D Toboni, et al.
Cancer Immunology Research|February 6, 2026
Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trialRashmi Mishra, Foluso Ademuyiwa, Yilin Yang, et al.
Communications Biology|July 3, 2023
Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survivalEmilee N Kotnik, Mary M Mullen, Nicholas C Spies, et al.
Biorxiv : the Preprint Server for Biology|October 3, 2025
Targeting RAD52 overcomes PARP inhibitor resistance in preclinical <i>Brca2</i>-deficient ovarian cancer modelYukihide Ota, Vijayalaxmi Gupta, Bisiayo E Fashemi, et al.
Cancer Immunology Research|June 17, 2017
Breast Cancer Neoantigens Can Induce CD8<sup>+</sup> T-Cell Responses and Antitumor ImmunityXiuli Zhang, Samuel Kim, Jasreet Hundal, et al.
The Journal of Clinical Investigation|May 20, 2025
Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancerAngela Schab, Amanda Compadre, Rebecca Drexler, et al.
Molecular Cancer Research : MCR|August 1, 2023
Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix ProteinsAngela M Schab, Molly M Greenwade, Elizabeth Stock, et al.
Pageof 14